Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TAFAMIDIS Cause Chronic obstructive pulmonary disease? 23 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Chronic obstructive pulmonary disease have been filed in association with TAFAMIDIS (Vyndamax). This represents 0.3% of all adverse event reports for TAFAMIDIS.

23
Reports of Chronic obstructive pulmonary disease with TAFAMIDIS
0.3%
of all TAFAMIDIS reports
6
Deaths
13
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From TAFAMIDIS?

Of the 23 reports, 6 (26.1%) resulted in death, 13 (56.5%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TAFAMIDIS. However, 23 reports have been filed with the FAERS database.

What Other Side Effects Does TAFAMIDIS Cause?

Death (2,553) Dyspnoea (608) Off label use (571) Cardiac failure (444) Fatigue (438) Fall (372) Malaise (301) Hypoacusis (298) Atrial fibrillation (296) Asthenia (256)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which TAFAMIDIS Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

TAFAMIDIS vs TAFAMIDIS MEGLUMINE TAFAMIDIS vs TAFASITAMAB TAFAMIDIS vs TAFASITAMAB-CXIX TAFAMIDIS vs TAFINLAR TAFAMIDIS vs TAFLUPROST

Related Pages

TAFAMIDIS Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease TAFAMIDIS Demographics